Therapeutic effect of bevacizumab injected into the silicone oil in eyes with neovascular glaucoma after vitrectomy for advanced diabetic retinopathy

被引：44

作者：

Falavarjani, K. Ghasemi ^{[1
]}

Modarres, M. ^{[1
]}

Nazari, H. ^{[1
]}

机构：

[1] Iran Univ Med Sci, Dept Ophthalmol, Tehran 14455364, Iran

来源：

EYE | 2010年 / 24卷 / 04期

关键词：

bevacizumab; silicone oil; vitrectomy; neovascular glaucoma; diabetic retinopathy; ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL BEVACIZUMAB; IRIS NEOVASCULARIZATION; AVASTIN; SECONDARY; AMD;

D O I：

10.1038/eye.2009.94

中图分类号：

R77 [眼科学];

学科分类号：

100212 [眼科学];

摘要：

Purpose To evaluate the effect of intra-silicone injection of bevacizumab for the treatment of neovascular glaucoma (NVG) after vitrectomy for advanced proliferative diabetic retinopathy. Methods Bevacizumab was injected into the silicone oil in five pseudophakic eyes of five patients with NVG. The iris neovascularization (INV) and NVG had developed 1.5-4 months after vitrectomy and silicone oil tamponade. The main outcome measures were regression of INV, intraocular pressure and visual acuity. Results In all eyes, INV regressed and intraocular pressure was controlled within 7 days. Visual acuity improved in all eyes. In one patient, INV and NVG recurred 10 weeks after the injection and was successfully treated with a repeat intra-silicone bevacizumab injection. Conclusion Intra-silicone injection of bevacizumab is effective in the treatment of patients with INV and NVG after vitrectomy for advanced proliferative diabetic retinopathy. Eye (2010) 24, 717-719; doi: 10.1038/eye.2009.94; published online 1 May 2009

引用

页码：717 / 719

页数：3

共 14 条

[1]

AVERY RL, 2008, RETINA TODAY MAR, P50

[2]

Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients [J].

Beer, Paul M. ;

Wong, Susan J. ;

Hammad, Amjad M. ;

Falk, Naomi S. ;

O'Malley, Martin R. ;

Khan, Samira .

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2006, 26 (08) :871-876

[3]

Cheng JYC, 2008, ANN ACAD MED SINGAP, V37, P72

[4]

Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA study): Results of a phase 1 dose-escalation study [J].

Costa, Rogerio A. ;

Jorge, Rodrigo ;

Calucci, Daniela ;

Cardillo, Jose A. ;

Melo, Luiz A. S., Jr. ;

Scott, Ingrid U. .

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2006, 47 (10) :4569-4578

[5]

Vascular endothelial growth factor: Basic science and clinical progress [J].

Ferrara, N .

ENDOCRINE REVIEWS, 2004, 25 (04) :581-611

[6]

Gallemore RP, 2006, RETINA, P2211

[7]

Intracameral bevacizumab for iris rubeosis [J].

Grisanti, Salvatore ;

Biester, Sabine ;

Peters, Swaantje ;

Tatar, Olcay ;

Ziemssen, Focke ;

Bartz-Schmidt, Karl Ulrich .

AMERICAN JOURNAL OF OPHTHALMOLOGY, 2006, 142 (01) :158-160

[8]

Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab [J].

Kiss, Christopher ;

Michels, Stephan ;

Prager, Franz ;

Weigert, Guenther ;

Geitzenauer, Wolfgang ;

Schmidt-Erfurth, Ursula .

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2006, 26 (08) :877-881

[9]

Testing intravitireal toxicity of bevacizumab (Avastin) [J].

Manzano, Roberta P. A. ;

Peyman, Gholam A. ;

Khan, Palwasha ;

Kivilcim, Muhamet .

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2006, 26 (03) :257-261

[10]

INTRAVITREAL INJECTION OF 2.5 MG VERSUS 1.25 MG BEVACIZUMAB (AVASTIN) FOR TREATMENT OF CNV ASSOCIATED WITH AMD [J].

Modarres, Mehdi ;

Naseripour, Masood ;

Falavarjani, Khalil Ghasemi ;

Nikeghbali, Aminollah ;

Hashemi, Masih ;

Parvaresh, Mohammad Mehdi .

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2009, 29 (03) :319-324

← 1 2 →